In a recent conversation with Dr. Andy Beck, co-founder and CEO of PathAI, we had the opportunity to discuss PathExplore, an AI-driven platform that aims to transform the way tumor microenvironment (TME) analysis is conducted. Traditional methods such as manual pathology, multiplex immunofluorescence and single-cell omics often face limitations, including high costs or tissue consumption.…
How AI technology can democratize clinical trials in oncology
While drug developers continue to develop promising investigational cancer drugs, conducting clinical research in oncology remains difficult. Here’s how AI-enabled software can help. The statistics on inadequate trial recruitment and endemic challenges in oncology clinical trials are well known. They have only gotten worse over the past 20 years. While the number of cancer treatments…